176 related articles for article (PubMed ID: 34685455)
1. Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma.
Vasileva N; Ageenko A; Dmitrieva M; Nushtaeva A; Mishinov S; Kochneva G; Richter V; Kuligina E
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685455
[TBL] [Abstract][Full Text] [Related]
2. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
3. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
[TBL] [Abstract][Full Text] [Related]
4. The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.
Vasileva NS; Ageenko AB; Richter VA; Kuligina EV
Acta Naturae; 2022; 14(2):62-70. PubMed ID: 35923561
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
[TBL] [Abstract][Full Text] [Related]
7. Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.
Dymova MA; Malysheva DO; Popova VK; Dmitrienko EV; Endutkin AV; Drokov DV; Mukhanov VS; Byvakina AA; Kochneva GV; Artyushenko PV; Shchugoreva IA; Rogova AV; Tomilin FN; Kichkailo AS; Richter VA; Kuligina EV
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398600
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
9. An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy.
Deng L; Yang X; Fan J; Ding Y; Peng Y; Xu D; Huang B; Hu Z
Onco Targets Ther; 2020; 13():3535-3544. PubMed ID: 32425553
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
11. GMCSF-armed vaccinia virus induces an antitumor immune response.
Parviainen S; Ahonen M; Diaconu I; Kipar A; Siurala M; Vähä-Koskela M; Kanerva A; Cerullo V; Hemminki A
Int J Cancer; 2015 Mar; 136(5):1065-72. PubMed ID: 25042001
[TBL] [Abstract][Full Text] [Related]
12. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
de Vries CR; Monken CE; Lattime EC
Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A; Kangasniemi L; Escutenaire S; Pesonen S; Cerullo V; Diaconu I; Nokisalmi P; Raki M; Rajecki M; Guse K; Ranki T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Laasonen L; Partanen K; Ugolini M; Helminen A; Karli E; Hannuksela P; Pesonen S; Joensuu T; Kanerva A; Hemminki A
Mol Ther; 2010 Oct; 18(10):1874-84. PubMed ID: 20664527
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG
Hum Vaccin Immunother; 2015; 11(7):1573-84. PubMed ID: 25996182
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Fend L; Remy-Ziller C; Foloppe J; Kempf J; Cochin S; Barraud L; Accart N; Erbs P; Fournel S; Préville X
Oncoimmunology; 2016 Feb; 5(2):e1080414. PubMed ID: 27057460
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
[TBL] [Abstract][Full Text] [Related]
18. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
[TBL] [Abstract][Full Text] [Related]
20. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
Ho TY; Mealiea D; Okamoto L; Stojdl DF; McCart JA
Mol Ther Oncolytics; 2021 Sep; 22():85-97. PubMed ID: 34514091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
